Skip to main content

Serious Gram-negative Infections

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Wockhardt
WockhardtNJ - Parsippany
1 program
1
Intravenous infusions of WCK 5222Phase 11 trial
Active Trials
NCT02707107Completed20Est. Apr 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
WockhardtIntravenous infusions of WCK 5222

Clinical Trials (1)

Total enrollment: 20 patients across 1 trials

NCT02707107WockhardtIntravenous infusions of WCK 5222

MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers

Start: Mar 2016Est. completion: Apr 201620 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.